Navigation Links
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Biocodex in France
Date:3/13/2017

TEL AVIV, Israel, March 13, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.

Neurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.

Biocodex promotes Circadin®, prolonged-release melatonin 2mg, indicated to treat primary insomnia in the elderly, since 2013 in France. "Biocodex played a significant role in obtaining reimbursement for Circadin under a Temporary Recommendation for Use (RTU) for treating sleep disorders in children with neurodevelopmental disorders. It was only natural that the collaboration will deepen to include PedPRM," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals. "Additional agreements are expected to follow in order to make the new treatment accessible for children and their families."

"Sleep disturbances in children presenting with neurodevelopment disabilities represent an unresolved therapeutic challenge. In addition to Circadin® for the treatment of primary insomnia in adults, Biocodex is pleased to expand its productive partnership with Neurim and is proud to continue the work being done on the RTU in order to make this new promising product available for these children in France," said Paul Bernasconi, MD, Vice President France Operations of Biocodex.

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM has recently completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

Contact:
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2019)... ... May 23, 2019 , ... ZVOX Audio , ... the AccuVoice AV50 Noise-Cancelling Headphone. The latest addition to the ZVOX family of ... AV50 is the first high-performance noise cancelling headphone from a major audio brand ...
(Date:5/23/2019)... ... 23, 2019 , ... Date aired: May 20th, 2019 , ... manager at Bunzl Safety, Canada ( https://www.bunzlcanada.ca/news/acquisition-announcement ) , “Your relationship to water,” ... Sharon Kleyne Hour Water Life Science®/Nature’s Pharma®, The Power of Water® & Your ...
(Date:5/23/2019)... ... May 23, 2019 , ... NATIONAL OFFICE – BKD CPAs & ... industry partner (NIP) of the health care practice. Former NIP Eddie Marmouget will transition ... be chosen to lead our national health care practice and work more closely with ...
Breaking Medicine Technology:
(Date:5/22/2019)... ... May 22, 2019 , ... Hypertrophic ... in every 500 people within the general population. Hypertrophic cardiomyopathy occurs if heart ... thicken. The thickened heart muscle can make it harder for the heart to ...
(Date:5/22/2019)... ... May 22, 2019 , ... ... Solutions LLC is a finalist for the Entrepreneur Of The Year® 2019 ... business awards programs in the U.S., the program recognizes entrepreneurs and leaders of ...
(Date:5/22/2019)... ... ... announced the release of The Ins and Outs of Vaping. The latest guide breaks down ... benefits it offers. , According to Vib, “Even though the key initial impulse ... there are lots of hidden benefits and reasons to vape.” , The guide first ...
(Date:5/22/2019)... ... May 22, 2019 , ... The Josh ... the availability of Wellbeing at Work, an Academy program developed in partnership with ... offers guidance and best-practice examples for creating a holistic corporate wellbeing program and ...
(Date:5/22/2019)... ... May 22, 2019 , ... ... Invisalign orthodontics solution to patients with crooked teeth in North Charleston, ... traditional orthodontics, giving patients more discretion, flexibility, and confidence in the process ...
Breaking Medicine News(10 mins):